134 related articles for article (PubMed ID: 35362874)
1. Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.
Ishi Y; Yamaguchi S; Okamoto M; Sawaya R; Endo S; Motegi H; Terasaka S; Tanei ZI; Hatanaka KC; Tanaka S; Fujimura M
Brain Tumor Pathol; 2022 Jul; 39(3):162-170. PubMed ID: 35362874
[TBL] [Abstract][Full Text] [Related]
2. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
3. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features.
Natsumeda M; Chang M; Gabdulkhaev R; Takahashi H; Tsukamoto Y; Kanemaru Y; Okada M; Oishi M; Okamoto K; Rodriguez FJ; Kakita A; Fujii Y; Schreck KC
Brain Tumor Pathol; 2021 Jul; 38(3):228-233. PubMed ID: 34216310
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
5. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
Shibahara I; Sonoda Y; Suzuki H; Mayama A; Kanamori M; Saito R; Suzuki Y; Mashiyama S; Uenohara H; Watanabe M; Kumabe T; Tominaga T
Brain Tumor Pathol; 2018 Jan; 35(1):10-18. PubMed ID: 29138945
[TBL] [Abstract][Full Text] [Related]
7. BRAF
Wang W; Wang M; Jiang H; Wang T; Da R
BMC Neurol; 2021 May; 21(1):195. PubMed ID: 33980169
[TBL] [Abstract][Full Text] [Related]
8. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
[TBL] [Abstract][Full Text] [Related]
10. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
11. Adult classical glioblastoma with a BRAF V600E mutation.
Takahashi Y; Akahane T; Sawada T; Ikeda H; Tempaku A; Yamauchi S; Nishihara H; Tanaka S; Nitta K; Ide W; Hashimoto I; Kamada H
World J Surg Oncol; 2015 Mar; 13():100. PubMed ID: 25885250
[TBL] [Abstract][Full Text] [Related]
12. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
[TBL] [Abstract][Full Text] [Related]
14. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults.
Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK
Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
16. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
[TBL] [Abstract][Full Text] [Related]
17. Epithelioid GBMs show a high percentage of BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Birks DK; Foreman NK
Am J Surg Pathol; 2013 May; 37(5):685-98. PubMed ID: 23552385
[TBL] [Abstract][Full Text] [Related]
18. Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.
Hata N; Hatae R; Yoshimoto K; Murata H; Kuga D; Akagi Y; Sangatsuda Y; Suzuki SO; Iwaki T; Mizoguchi M; Iihara K
Neuropathology; 2017 Jun; 37(3):200-206. PubMed ID: 28116838
[TBL] [Abstract][Full Text] [Related]
19. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
20. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
